- Home
- MDRR vs IBIO Comparison
MDRR vs IBIO Comparison
Compare MDRR & IBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MDRR
- IBIO
- Stock Information
- Founded
- MDRR 2015
- IBIO 2008
- Country
- MDRR United States
- IBIO United States
- Employees
- MDRR N/A
- IBIO N/A
- Industry
- MDRR Real Estate Investment Trusts
- IBIO Biotechnology: Pharmaceutical Preparations
- Sector
- MDRR Real Estate
- IBIO Health Care
- Exchange
- MDRR Nasdaq
- IBIO Nasdaq
- Market Cap
- MDRR 15.6M
- IBIO 15.9M
- IPO Year
- MDRR 2018
- IBIO N/A
- Fundamental
- Price
- MDRR $11.22
- IBIO $0.81
- Analyst Decision
- MDRR
- IBIO Strong Buy
- Analyst Count
- MDRR 0
- IBIO 3
- Target Price
- MDRR N/A
- IBIO $4.87
- AVG Volume (30 Days)
- MDRR 1.9K
- IBIO 5.4M
- Earning Date
- MDRR 08-08-2025
- IBIO 05-02-2025
- Dividend Yield
- MDRR 2.40%
- IBIO N/A
- EPS Growth
- MDRR N/A
- IBIO N/A
- EPS
- MDRR N/A
- IBIO N/A
- Revenue
- MDRR $9,485,128.00
- IBIO $375,000.00
- Revenue This Year
- MDRR N/A
- IBIO $36.00
- Revenue Next Year
- MDRR N/A
- IBIO N/A
- P/E Ratio
- MDRR N/A
- IBIO N/A
- Revenue Growth
- MDRR N/A
- IBIO 650.00
- 52 Week Low
- MDRR $9.55
- IBIO $0.64
- 52 Week High
- MDRR $15.00
- IBIO $6.89
- Technical
- Relative Strength Index (RSI)
- MDRR 52.10
- IBIO 47.34
- Support Level
- MDRR $10.09
- IBIO $0.71
- Resistance Level
- MDRR $11.43
- IBIO $0.87
- Average True Range (ATR)
- MDRR 0.45
- IBIO 0.08
- MACD
- MDRR 0.00
- IBIO 0.02
- Stochastic Oscillator
- MDRR 85.57
- IBIO 37.39
About MDRR Medalist Diversified REIT Inc.
Medalist Diversified REIT Inc is engaged to acquire, reposition, renovate, lease, and manage income-producing properties with a focus on commercial properties, including flex-industrial and retail properties, multi-family residential properties, and hotel properties. The company operates as a UPREIT and owns properties through its subsidiary, Medalist Diversified Holdings, LP. Its reportable segments were retail center properties, flex center properties, and STNL properties.
About IBIO iBio Inc.
iBio Inc is a preclinical stage biotechnology company that leverages the power of Artificial Intelligence (AI) for the development of precision antibodies. CDMO. Its technology stack is designed to minimize downstream development risks by employing AI-guided epitope-steering and monoclonal antibody (mAb) optimization.